Security key
83086J200
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE)
CUSIP: 83086J200
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001
- Shares outstanding
- 33,945,050
- Total 13F shares
- 24,496,645
- Share change
- +22,450,365
- Total reported value
- $196,252,371
- Put/Call ratio
- 100%
- Price per share
- $8.01
- Number of holders
- 62
- Value change
- +$179,861,577
- Number of buys
- 58
Report period
Q2 2024
Institutions
62
Top holders
10
SKYE full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Skye Bioscience, Inc. SEC filings
Skye Bioscience, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 83086J200
Recent filing periods:
Top shareholders of SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Versant Venture Management, LLC |
13F
|
Company |
5.9%
|
2,007,702
|
$31,400,459 | — | 31 Mar 2024 | |
| Financial Gravity Asset Management, Inc. |
13F
|
Company |
0%
|
1,600
|
$4,352 | — | 31 Mar 2024 | |
| TUCKER ASSET MANAGEMENT LLC |
13F
|
Company |
0%
|
1
|
$16 | — | 31 Mar 2024 | |
| Versant Ventures III, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
501,925,802
|
$9,386,012 | — | 18 Aug 2023 | |
| Emerald Health Sciences Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
169,407,901
|
$3,167,928 | — | 10 Nov 2022 | |
| James L. Heppell |
3/4/5
|
Director |
—
class O/S missing
|
1,350,000
|
— | — | 14 Sep 2021 | |
| Sukhwinder Singh Rai |
3/4/5
|
Director |
—
class O/S missing
|
250,000
|
— | — | 05 Jan 2023 | |
| Keith Wayne Ward |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 29 Feb 2024 | |
| Margaret Dalesandro |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 29 Feb 2024 | |
| Praveen Tyle |
3/4/5
|
Director |
—
class O/S missing
|
35,000
|
— | — | 29 Feb 2024 |
Institutional Holders of Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) as of Q2 2024
As of 30 Jun 2024,
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,496,645 shares.
The largest 10 holders included
5AM Venture Management, LLC, Versant Venture Management, LLC, Altium Capital Management LP, Logos Global Management LP, SPHERA FUNDS MANAGEMENT LTD., BlackRock Inc., JANUS HENDERSON GROUP PLC, VANGUARD GROUP INC, CVI Holdings, LLC, and Driehaus Capital Management LLC.
This page lists
62
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
3
Q2 2024 holders
62
Holder diff
59
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.